A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma.
TNFRSF12A
glioma
immune
malignant progression
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
12
2020
accepted:
23
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Glioma is one of the most common malignancies in the central nervous system and has limited effective therapeutic options. Therefore, we sought to identify a suitable target for immunotherapy. We screened prognostic genes for glioma in the CGGA database and GSE43378 dataset using survival analysis, receiver operating characteristic (ROC) curves, independent prognostic analysis, and clinical correlation analysis. The results were intersected with immune genes from the ImmPort database through Venn diagrams to obtain likely target genes. The target genes were validated as prognostically relevant immune genes for glioma using survival, ROC curve, independent prognostic, and clinical correlation analyses in samples from the CGGA database and GSE43378 dataset, respectively. We also constructed a nomogram using statistically significant glioma prognostic factors in the CGGA samples and verified their sensitivity and specificity with ROC curves. The functions, pathways, and co-expression-related genes for the glioma target genes were assessed using PPI networks, enrichment analysis, and correlation analysis. The correlation between target gene expression and immune cell infiltration in glioma and the relationship with the survival of glioma patients were investigated using the TIMER database. Finally, target gene expression in normal brain, low-grade glioma, and high-grade glioma tissues was detected using immunohistochemical staining. We identified TNFRSF12A as the target gene. Satisfactory results from survival, ROC curve, independent prognosis, and clinical correlation analyses in the CGGA and GSE43378 samples verified that TNFRSF12A was significantly associated with the prognosis of glioma patients. A nomogram was constructed using glioma prognostic correlates, including TNFRSF12A expression, primary-recurrent-secondary (PRS) type, grade, age, chemotherapy, IDH mutation, and 1p19q co-deletion in CGGA samples with an AUC value of 0.860, which illustrated the accuracy of the prognosis prediction. The results of the TIMER analysis validated the significant correlation of TNFRSF12A with immune cell infiltration and glioma survival. The immunohistochemical staining results verified the progressive up-regulation of TNFRSF12A expression in normal brain, low-grade glioma, and high-grade glioma tissues. We concluded that TNFRSF12A was a viable prognostic biomarker and a potential immunotherapeutic target for glioma.
Sections du résumé
BACKGROUND
BACKGROUND
Glioma is one of the most common malignancies in the central nervous system and has limited effective therapeutic options. Therefore, we sought to identify a suitable target for immunotherapy.
MATERIALS AND METHODS
METHODS
We screened prognostic genes for glioma in the CGGA database and GSE43378 dataset using survival analysis, receiver operating characteristic (ROC) curves, independent prognostic analysis, and clinical correlation analysis. The results were intersected with immune genes from the ImmPort database through Venn diagrams to obtain likely target genes. The target genes were validated as prognostically relevant immune genes for glioma using survival, ROC curve, independent prognostic, and clinical correlation analyses in samples from the CGGA database and GSE43378 dataset, respectively. We also constructed a nomogram using statistically significant glioma prognostic factors in the CGGA samples and verified their sensitivity and specificity with ROC curves. The functions, pathways, and co-expression-related genes for the glioma target genes were assessed using PPI networks, enrichment analysis, and correlation analysis. The correlation between target gene expression and immune cell infiltration in glioma and the relationship with the survival of glioma patients were investigated using the TIMER database. Finally, target gene expression in normal brain, low-grade glioma, and high-grade glioma tissues was detected using immunohistochemical staining.
RESULTS
RESULTS
We identified TNFRSF12A as the target gene. Satisfactory results from survival, ROC curve, independent prognosis, and clinical correlation analyses in the CGGA and GSE43378 samples verified that TNFRSF12A was significantly associated with the prognosis of glioma patients. A nomogram was constructed using glioma prognostic correlates, including TNFRSF12A expression, primary-recurrent-secondary (PRS) type, grade, age, chemotherapy, IDH mutation, and 1p19q co-deletion in CGGA samples with an AUC value of 0.860, which illustrated the accuracy of the prognosis prediction. The results of the TIMER analysis validated the significant correlation of TNFRSF12A with immune cell infiltration and glioma survival. The immunohistochemical staining results verified the progressive up-regulation of TNFRSF12A expression in normal brain, low-grade glioma, and high-grade glioma tissues.
CONCLUSION
CONCLUSIONS
We concluded that TNFRSF12A was a viable prognostic biomarker and a potential immunotherapeutic target for glioma.
Identifiants
pubmed: 33937046
doi: 10.3389/fonc.2021.643159
pmc: PMC8085360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
643159Informations de copyright
Copyright © 2021 Zhang, Yang, Zhu, Wang, Bai, Zhang, Hao and Duan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Trends Cancer. 2018 Sep;4(9):605-607
pubmed: 30149878
Nat Genet. 2016 Jul;48(7):768-76
pubmed: 27270107
Cytokine Growth Factor Rev. 2019 Jun;47:54-61
pubmed: 31122819
Adv Cancer Res. 2019;142:145-186
pubmed: 30885361
Cell Death Dis. 2019 Feb 15;10(3):162
pubmed: 30770791
J Exp Clin Cancer Res. 2019 Feb 18;38(1):87
pubmed: 30777100
Oncol Rep. 2016 Aug;36(2):1030-40
pubmed: 27350337
Immunol Rev. 2011 Nov;244(1):99-114
pubmed: 22017434
Am J Pathol. 2003 Apr;162(4):1313-21
pubmed: 12651623
J Transl Med. 2019 Sep 9;17(1):307
pubmed: 31500625
Genome Res. 2015 Mar;25(3):316-27
pubmed: 25650244
J Invest Dermatol. 2013 Apr;133(4):1052-62
pubmed: 23190886
Neuro Oncol. 2020 May 15;22(5):665-674
pubmed: 31621885
Curr Opin Rheumatol. 2019 Nov;31(6):669-677
pubmed: 31415031
PLoS One. 2013 Jun 04;8(6):e65248
pubmed: 23750247
Clin Cancer Res. 2017 Jul 15;23(14):3575-3584
pubmed: 28193626
J Neurooncol. 2018 Jun;138(2):241-250
pubmed: 29453678
Mini Rev Med Chem. 2004 Jun;4(5):563-83
pubmed: 15180511
J Exp Med. 2013 Dec 16;210(13):2803-11
pubmed: 24277150
Cancer Res. 2013 Jul 15;73(14):4439-50
pubmed: 23722548
World Neurosurg. 2020 Feb;134:e761-e770
pubmed: 31712116
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150
pubmed: 28815663
Int J Oncol. 2014 Feb;44(2):583-90
pubmed: 24337061
Mol Cancer Res. 2012 Jul;10(7):958-68
pubmed: 22571869
Cancer Res. 2017 Apr 1;77(7):1709-1718
pubmed: 28202508
Biomaterials. 2015 Feb;42:42-51
pubmed: 25542792
Cell. 2015 Sep 10;162(6):1365-78
pubmed: 26359988
Oncotarget. 2017 Feb 14;8(7):12234-12246
pubmed: 28103571
Neuro Oncol. 2018 Sep 3;20(10):1321-1330
pubmed: 29897522
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Front Immunol. 2013 Nov 11;4:367
pubmed: 24273541
J Control Release. 2017 Dec 10;267:144-153
pubmed: 28887134
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
Nat Rev Drug Discov. 2008 May;7(5):411-25
pubmed: 18404150
Pharmacol Ther. 2018 Apr;184:13-41
pubmed: 29080702
Clin Cancer Res. 2013 Oct 15;19(20):5686-98
pubmed: 23974006
J Neuroinflammation. 2013 Mar 09;10:36
pubmed: 23497038
Front Immunol. 2013 Dec 25;4:484
pubmed: 24400009
J Neurosurg. 2019 May 31;132(6):1970-1976
pubmed: 31151100
Expert Rev Neurother. 2016 Sep;16(9):1055-65
pubmed: 27228211
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Mol Cancer Res. 2016 Mar;14(3):302-12
pubmed: 26764186
Semin Immunol. 2014 Jun;26(3):229-36
pubmed: 24636536
Cancer Res. 2006 Oct 1;66(19):9535-42
pubmed: 17018610
J Surg Oncol. 2018 Aug;118(2):356-361
pubmed: 30125355
Annu Rev Med. 2007;58:221-37
pubmed: 17059365
Clin Cancer Res. 2018 Jan 15;24(2):295-305
pubmed: 29074604
Mol Cancer. 2015 Jan 27;14:9
pubmed: 25622756
Front Immunol. 2017 Nov 16;8:1534
pubmed: 29201025
Trends Mol Med. 2018 Jan;24(1):49-65
pubmed: 29217118
Immunity. 2001 Nov;15(5):837-46
pubmed: 11728344
Mol Cancer Ther. 2011 Jul;10(7):1276-88
pubmed: 21586630
Oncogene. 2019 Aug;38(35):6241-6255
pubmed: 31312026
Oncogene. 2016 Apr 28;35(17):2145-55
pubmed: 26300004
Physiol Rev. 2019 Jan 1;99(1):115-160
pubmed: 30354964
Cancer Res. 2009 Mar 1;69(5):2091-9
pubmed: 19244127
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570